AB748,21,44 4. Evidence of financial responsibility of at least $1,000,000.
AB748,21,55 5. Any other information required by the commissioner.
AB748,21,76 (b) The term of a license issued under par. (a) shall be 2 years from the date of
7issuance.
AB748,21,11 8(3) Disclosure to the commissioner. (a) A pharmacy services administrative
9organization licensed under sub. (2) shall disclose to the commissioner the extent of
10any ownership or control of the pharmacy services administrative organization by
11an entity that does any of the following:
AB748,21,1212 1. Provides pharmacy services.
AB748,21,1313 2. Provides prescription drug or device services.
AB748,21,1514 3. Manufactures, sells, or distributes prescription drugs, biologicals, or medical
15devices.
AB748,21,1816 (b) A pharmacy services administrative organization licensed under sub. (2)
17shall notify the commissioner in writing within 5 days of any material change in its
18ownership or control relating to an entity described in par. (a).
AB748,21,19 19(4) Rules. The commissioner may promulgate rules to implement this section.
AB748,16 20Section 16 . 632.865 (2m) of the statutes is created to read:
AB748,21,2421 632.865 (2m) Fiduciary duty and disclosures to health benefit plan
22sponsors.
(a) A pharmacy benefit manager owes a fiduciary duty to the health
23benefit plan sponsor to act according to the health benefit plan sponsor's instructions
24and in the best interests of the health benefit plan sponsor.
AB748,22,3
1(b) A pharmacy benefit manager shall annually provide, no later than the date
2and using the method prescribed by the commissioner by rule, the health benefit plan
3sponsor all of the following information from the previous calendar year:
AB748,22,54 1. The indirect profit received by the pharmacy benefit manager from owning
5any interest in a pharmacy or service provider.
AB748,22,76 2. Any payment made by the pharmacy benefit manager to a consultant or
7broker who works on behalf of the health benefit plan sponsor.
AB748,22,118 3. From the amounts received from all drug manufacturers, the amounts
9retained by the pharmacy benefit manager, and not passed through to the health
10benefit plan sponsor, that are related to the health benefit plan sponsor's claims or
11bona fide service fees.
AB748,22,1612 4. The amounts, including pharmacy access and audit recovery fees, received
13from all pharmacies that are in the pharmacy benefit manager's network or have a
14contract to be in the network and, from these amounts, the amount retained by the
15pharmacy benefit manager and not passed through to the health benefit plan
16sponsor.
AB748,17 17Section 17 . 632.868 of the statutes is created to read:
AB748,22,18 18632.868 Insulin safety net programs. (1) Definitions. In this section:
AB748,22,2019 (a) “Manufacturer" means a person engaged in the manufacturing of insulin
20that is self-administered on an outpatient basis.
AB748,22,2121 (b) “Navigator" has the meaning given in s. 628.90 (3).
AB748,22,2322 (c) “Patient assistance program” means a program established by a
23manufacturer under sub. (3) (a).
AB748,22,2424 (d) “Pharmacy" means an entity licensed under s. 450.06 or 450.065.
AB748,23,3
1(e) “Urgent need of insulin" means having less than a 7-day supply of insulin
2readily available for use and needing insulin in order to avoid the likelihood of
3suffering a significant health consequence.
AB748,23,54 (f) “Urgent need safety net program” means a program established by a
5manufacturer under sub. (2) (a).
AB748,23,9 6(2) Urgent need safety net program. (a) Establishment of program. No later
7than July 1, 2024, each manufacturer shall establish an urgent need safety net
8program to make insulin available in accordance with this subsection to individuals
9who meet the eligibility requirements under par. (b).
AB748,23,1110 (b) Eligible individual. An individual shall be eligible to receive insulin under
11an urgent need safety net program if all of the following conditions are met:
AB748,23,1212 1. The individual is in urgent need of insulin.
AB748,23,1313 2. The individual is a resident of this state.
AB748,23,1414 3. The individual is not receiving public assistance under ch. 49.
AB748,23,1915 4. The individual is not enrolled in prescription drug coverage through an
16individual or group health plan that limits the total cost sharing amount, including
17copayments, deductibles, and coinsurance, that an enrollee is required to pay for a
1830-day supply of insulin to no more than $75, regardless of the type or amount of
19insulin prescribed.
AB748,23,2120 5. The individual has not received insulin under an urgent need safety net
21program within the previous 12 months, except as allowed under par. (d).
AB748,23,2522 (c) Provision of insulin under an urgent need safety net program. 1. In order
23to receive insulin under an urgent need safety net program, an individual who meets
24the eligibility requirements under par. (b) shall provide a pharmacy with all of the
25following:
AB748,24,4
1a. A completed application, on a form prescribed by the commissioner that shall
2include an attestation by the individual, or the individual's parent or legal guardian
3if the individual is under the age of 18, that the individual meets all of the eligibility
4requirements under par. (b).
AB748,24,55 b. A valid insulin prescription.
AB748,24,86 c. A valid Wisconsin driver's license or state identification card. If the
7individual is under the age of 18, the individual's parent or legal guardian shall meet
8this requirement.
AB748,24,169 2. Upon receipt of the information described in subd. 1. a. to c., the pharmacist
10shall dispense a 30-day supply of the prescribed insulin to the individual. The
11pharmacy shall also provide the individual with the information sheet described in
12sub. (8) (b) 2. and the list of navigators described in sub. (8) (c). The pharmacy may
13collect a copayment, not to exceed $35, from the individual to cover the pharmacy's
14costs of processing and dispensing the insulin. The pharmacy shall notify the health
15care practitioner who issued the prescription no later than 72 hours after the insulin
16is dispensed.
AB748,24,2417 3. A pharmacy that dispenses insulin under subd. 2. may submit to the
18manufacturer, or the manufacturer's vendor, a claim for payment that is in
19accordance with the national council for prescription drug programs' standards for
20electronic claims processing, except that no claim may be submitted if the
21manufacturer agrees to send the pharmacy a replacement of the same insulin in the
22amount dispensed. If the pharmacy submits an electronic claim, the manufacturer
23or vendor shall reimburse the pharmacy in an amount that covers the pharmacy's
24acquisition cost.
AB748,25,2
14. A pharmacy that dispenses insulin under subd. 2. shall retain a copy of the
2application form described in subd. 1. a.
AB748,25,93 (d) Eligibility of certain individuals. An individual who has applied for public
4assistance under ch. 49 but for whom a determination of eligibility has not been made
5or whose coverage has not become effective or an individual who has an appeal
6pending under sub. (3) (c) 4. may access insulin under this subsection if the
7individual is in urgent need of insulin. To access a 30-day supply of insulin, the
8individual shall attest to the pharmacy that the individual is described in this
9paragraph and comply with par. (c) 1.
AB748,25,14 10(3) Patient assistance program. (a) Establishment of program. No later than
11July 1, 2024, each manufacturer shall establish a patient assistance program to
12make insulin available in accordance with this subsection to individuals who meet
13the eligibility requirements under par. (b). Under the patient assistance program,
14the manufacturer shall do all of the following:
AB748,25,1715 1. Provide the commissioner with information regarding the patient assistance
16program, including contact information for individuals to call for assistance in
17accessing the patient assistance program.
AB748,25,1918 2. Provide a hotline for individuals to call or access between 8 a.m. and 10 p.m.
19on weekdays and between 10 a.m. and 6 p.m. on Saturdays.
AB748,25,2120 3. List the eligibility requirements under par. (b) on the manufacturer's
21website.
AB748,25,2522 4. Maintain the privacy of all information received from an individual applying
23for or participating in the patient assistance program and not sell, share, or
24disseminate the information unless required under this section or authorized, in
25writing, by the individual.
AB748,26,2
1(b) Eligible individual. An individual shall be eligible to receive insulin under
2a patient assistance program if all of the following conditions are met:
AB748,26,33 1. The individual is a resident of this state.
AB748,26,64 2. The individual, or the individual's parent or legal guardian if the individual
5is under the age of 18, has a valid Wisconsin driver's license or state identification
6card.
AB748,26,77 3. The individual has a valid insulin prescription.
AB748,26,108 4. The family income of the individual does not exceed 400 percent of the
9poverty line as defined and revised annually under 42 USC 9902 (2) for a family the
10size of the individual's family.
AB748,26,1111 5. The individual is not receiving public assistance under ch. 49.
AB748,26,1712 6. The individual is not eligible to receive health care through a federally
13funded program or receive prescription drug benefits through the U.S. department
14of veterans affairs, except that this subdivision does not apply to an individual who
15is enrolled in a policy under Part D of Medicare under 42 USC 1395w-101 et seq. if
16the individual has spent at least $1,000 on prescription drugs in the current calendar
17year.
AB748,26,2218 7. The individual is not enrolled in prescription drug coverage through an
19individual or group health plan that limits the total cost sharing amount, including
20copayments, deductibles, and coinsurance, that an enrollee is required to pay for a
2130-day supply of insulin to no more than $75, regardless of the type or amount of
22insulin needed.
AB748,27,623 (c) Application for patient assistance program. 1. An individual may apply to
24participate in a patient assistance program by filing an application with the
25manufacturer that established the patient assistance program, the individual's

1health care practitioner if the practitioner participates in the patient assistance
2program, or a navigator included on the list under sub. (8) (c). A health care
3practitioner or navigator shall immediately submit the application to the
4manufacturer. Upon receipt of an application, the manufacturer shall determine the
5individual's eligibility under par. (b) and, except as provided in subd. 2., notify the
6individual of the determination no later than 10 days after receipt of the application.
AB748,27,127 2. If necessary to determine the individual's eligibility under par. (b), the
8manufacturer may request additional information from an individual who has filed
9an application under subd. 1. no later than 5 days after receipt of the application.
10Upon receipt of the additional information, the manufacturer shall determine the
11individual's eligibility under par. (b) and notify the individual of the determination
12no later than 3 days after receipt of the requested information.
AB748,27,1813 3. Except as provided in subd. 5., if the manufacturer determines under subd.
141. or 2. that the individual is eligible for the patient assistance program, the
15manufacturer shall provide the individual with a statement of eligibility. The
16statement of eligibility shall be valid for 12 months and may be renewed upon a
17determination by the manufacturer that the individual continues to meet the
18eligibility requirements under par. (b).
AB748,28,419 4. If the manufacturer determines under subd. 1. or 2. that the individual is not
20eligible for the patient assistance program, the manufacturer shall provide the
21reason for the determination in the notification under subd. 1. or 2. The individual
22may appeal the determination by filing an appeal with the commissioner that shall
23include all of the information provided to the manufacturer under subds. 1. and 2.
24The commissioner shall establish procedures for deciding appeals under this
25subdivision. The commissioner shall issue a decision no later than 10 days after the

1appeal is filed, and the commissioner's decision shall be final. If the commissioner
2determines that the individual meets the eligibility requirements under par. (b), the
3manufacturer shall provide the individual with the statement of eligibility described
4in subd. 3.
AB748,28,135 5. In the case of an individual who has prescription drug coverage through an
6individual or group health plan, if the manufacturer determines under subd. 1. or 2.
7that the individual is eligible for the patient assistance program but also determines
8that the individual's insulin needs are better addressed through the use of the
9manufacturer's copayment assistance program rather than the patient assistance
10program, the manufacturer shall inform the individual of the determination and
11provide the individual with the necessary coupons to submit to a pharmacy. The
12individual may not be required to pay more than the copayment amount specified in
13par. (d) 2.
AB748,28,2014 (d) Provision of insulin under a patient assistance program. 1. Upon receipt
15from an individual of the eligibility statement described in par. (c) 3. and a valid
16insulin prescription, a pharmacy shall submit an order containing the name of the
17insulin and daily dosage amount to the manufacturer. The pharmacy shall include
18with the order the pharmacy's name, shipping address, office telephone number, fax
19number, email address, and contact name, as well as any days or times when
20deliveries are not accepted by the pharmacy.
AB748,29,421 2. Upon receipt of an order meeting the requirements under subd. 1., the
22manufacturer shall send the pharmacy a 90-day supply of insulin, or lesser amount
23if requested in the order, at no charge to the individual or pharmacy. The pharmacy
24shall dispense the insulin to the individual associated with the order. The insulin
25shall be dispensed at no charge to the individual, except that the pharmacy may

1collect a copayment from the individual to cover the pharmacy's costs for processing
2and dispensing in an amount not to exceed $50 for each 90-day supply of insulin.
3The pharmacy may not seek reimbursement from the manufacturer or a 3rd-party
4payer.
AB748,29,75 3. The pharmacy may submit a reorder to the manufacturer if the individual's
6eligibility statement described in par. (c) 3. has not expired. The reorder shall be
7treated as an order for purposes of subd. 2.
AB748,29,108 4. Notwithstanding subds. 2. and 3., a manufacturer may send the insulin
9directly to the individual if the manufacturer provides a mail-order service option,
10in which case the pharmacy may not collect a copayment from the individual.
AB748,29,13 11(4) Exceptions. (a) This section does not apply to a manufacturer that shows
12to the commissioner's satisfaction that the manufacturer's annual gross revenue
13from insulin sales in this state does not exceed $2,000,000.
AB748,29,1814 (b) A manufacturer may not be required to make an insulin product available
15under sub. (2) or (3) if the wholesale acquisition cost of the insulin product does not
16exceed $8, as adjusted annually based on the U.S. consumer price index for all urban
17consumers, U.S. city average, per milliliter or the applicable national council for
18prescription drug programs' plan billing unit.
AB748,29,21 19(5) Confidentiality. All medical information solicited or obtained by any
20person under this section shall be subject to the applicable provisions of state law
21relating to confidentiality of medical information, including s. 610.70.
AB748,30,2 22(6) Reimbursement prohibition. No person, including a manufacturer,
23pharmacy, pharmacist, or 3rd-party administrator, as part of participating in an
24urgent need safety net program or patient assistance program may request or seek,
25or cause another person to request or seek, any reimbursement or other

1compensation for which payment may be made in whole or in part under a federal
2health care program, as defined in 42 USC 1320a-7b (f).
AB748,30,5 3(7) Reports. (a) Annually, no later than March 1, each manufacturer shall
4report to the commissioner all of the following information for the previous calendar
5year:
AB748,30,76 1. The number of individuals who received insulin under the manufacturer's
7urgent need safety net program.
AB748,30,108 2. The number of individuals who sought assistance under the manufacturer's
9patient assistance program and the number of individuals who were determined to
10be ineligible under sub. (3) (c) 4.
AB748,30,1211 3. The wholesale acquisition cost of the insulin provided by the manufacturer
12through the urgent need safety net program and patient assistance program.
AB748,30,1613 (b) Annually, no later than April 1, the commissioner shall submit to the
14governor and the chief clerk of each house of the legislature, for distribution to the
15legislature under s. 13.172 (2), a report on the urgent need safety net programs and
16patient assistance programs that includes all of the following:
AB748,30,1717 1. The information provided to the commissioner under par. (a).
AB748,30,1918 2. The penalties assessed under sub. (9) during the previous calendar year,
19including the name of the manufacturer and amount of the penalty.
AB748,30,24 20(8) Additional responsibilities of commissioner. (a) Application form. The
21commissioner shall make the application form described in sub. (2) (c) 1. a. available
22on the office's website and shall make the form available to pharmacies and health
23care providers who prescribe or dispense insulin, hospital emergency departments,
24urgent care clinics, and community health clinics.
AB748,31,3
1(b) Public outreach. 1. The commissioner shall conduct public outreach to
2create awareness of the urgent need safety net programs and patient assistance
3programs.
AB748,31,54 2. The commissioner shall develop and make available on the office's website
5an information sheet that contains all of the following information:
AB748,31,76 a. A description of how to access insulin through an urgent need safety net
7program.
AB748,31,88 b. A description of how to access insulin through a patient assistance program.
AB748,31,109 c. Information on how to contact a navigator for assistance in accessing insulin
10through an urgent need safety net program or patient assistance program.
AB748,31,1211 d. Information on how to contact the commissioner if a manufacturer
12determines that an individual is not eligible for a patient assistance program.
AB748,31,1413 e. A notification that an individual may contact the commissioner for more
14information or assistance in accessing ongoing affordable insulin options.
AB748,31,2115 (c) Navigators. The commissioner shall develop a training program to provide
16navigators with information and the resources necessary to assist individuals in
17accessing appropriate long-term insulin options. The commissioner shall compile
18a list of navigators that have completed the training program and are available to
19assist individuals in accessing affordable insulin coverage options. The list shall be
20made available on the office's website and to pharmacies and health care
21practitioners who dispense and prescribe insulin.
AB748,32,222 (d) Satisfaction surveys. 1. The commissioner shall develop and conduct a
23satisfaction survey of individuals who have accessed insulin through urgent need
24safety net programs and patient assistance programs. The survey shall ask whether
25the individual is still in need of a long-term solution for affordable insulin and shall

1include questions about the individual's satisfaction with all of the following, if
2applicable:
AB748,32,33 a. Accessibility to urgent-need insulin.
AB748,32,54 b. Adequacy of the information sheet and list of navigators received from the
5pharmacy.
AB748,32,66 c. Helpfulness of a navigator.
AB748,32,87 d. Ease of access in applying for a patient assistance program and receiving
8insulin from the pharmacy under the patient assistance program.
AB748,32,129 2. The commissioner shall develop and conduct a satisfaction survey of
10pharmacies that have dispensed insulin through urgent need safety net programs
11and patient assistance programs. The survey shall include questions about the
12pharmacy's satisfaction with all of the following, if applicable:
AB748,32,1413 a. Timeliness of reimbursement from manufacturers for insulin dispensed by
14the pharmacy under urgent need safety net programs.
AB748,32,1515 b. Ease in submitting insulin orders to manufacturers.
Loading...
Loading...